Disappointing early results for niraparib plus dostarlimab in the treatment of relapsed endometrial or ovarian carcinosarcomas
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer
However, studies highlight cost as an obstacle to widespread accessibility in some countries
Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications
New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression
Durvalumab plus olaparib show sustained PFS improvements in newly diagnosed non-BRCA-mutated ovarian cancer
While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design
The promises of antibody-drug conjugates for ovarian cancer
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
A phase I study shows a promising strategy to overcome resistance to immunotherapy in cancer
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
Atezolizumab plus sacituzumab govitecan show encouraging activity in inoperable triple-negative breast cancer
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours
Triplet therapy shows promise in patients with ER positive/HER2 negative metastatic breast cancer
A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers
Novel scenarios in targeting HR-positive/HER2-negative breast cancer
Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor